Evolution of the Average Target: Afya Limited

Evolution of the Average Target - Afya Limited

Evolution of the Target Price: Afya Limited

Evolution of the Target Price - Afya Limited

Changes in Analyst Recommendations: Afya Limited

b.4PB0coqDmrqTNk3c6haFAMBrtN7aBqHTWrCqswcKxcQ.sLYlQ-LZ6vTYUB6xhi7sR7oi9467dO-EAMOf12tErPeimjoQwtbsy6MABA~ed04c67e73bbfacc430236cc21480c92
Oct. 07 Afya Shares Rise After JPMorgan Upgrade MT
Oct. 07 JPMorgan Upgrades Afya to Overweight From Neutral, $19 Price Target MT
Feb. 24 BofA Securities Downgrades Afya to Neutral From Buy, Price Target is $17 MT
Feb. 13 Afya Shares Fall After Morgan Stanley Downgrade MT
Feb. 13 Morgan Stanley Downgrades Afya to Underweight From Equalweight, Adjusts Price Target to $16 From $17.50 MT
Jan. 16 UBS Downgrades Afya to Neutral From Buy, Adjusts PT to $16 From $18 MT
Jan. 08 UBS Trims Afya Price Target to $18 From $19, Maintains Buy Rating MT
Jan. 07 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $22 From $24.50 MT
25-09-08 UBS Upgrades Afya to Buy From Neutral, $19 Price Target MT
25-09-08 JPMorgan Upgrades Afya to Overweight, Price Target is $24.50 MT
25-08-06 Afya Shares Rise After Morgan Stanley Upgrade MT
25-08-06 Morgan Stanley Upgrades Afya to Equalweight From Underweight, Adjusts Price Target to $17.50 From $19 MT
25-07-29 Citigroup Upgrades Afya to Neutral From Sell, Adjusts Price Target to $14 From $16 MT
25-06-12 UBS Hikes Afya Price Target to $19.50 From $17.50, Maintains Neutral Rating MT
25-03-11 Morgan Stanley Downgrades Afya to Underweight From Equal Weight, Cuts Price Target to $17 From $19 MT
25-02-05 Bradesco BBI Downgrades Afya to Underperform From Neutral, Adjusts Price Target to $14 From $17 MT
25-01-31 Citigroup Downgrades Afya to Sell From Neutral, Adjusts Price Target to $15 From $18 MT
24-12-17 UBS Cuts Price Target on Afya to $17.50 From $19.50, Keeps Neutral Rating MT
24-08-30 UBS Initiates Coverage on Afya With Neutral Rating, Sets $19.50 Price Target MT
24-06-21 Morgan Stanley Adjusts Price Target on Afya to $19 From $21, Maintains Equalweight Rating MT
23-11-27 JPMorgan Downgrades Afya to Neutral From Overweight, Adjusts Price Target to $23 From $22 MT
22-11-22 Credit Suisse Adjusts Afya's Price Target to $18 From $19, Keeps Outperform Rating MT
22-10-13 UBS Adjusts Afya Price Target to $18 From $21, Maintains Buy Rating MT
22-04-08 Credit Suisse Upgrades Afya to Outperform from Neutral, Adjusts Price Target to $19 from $18 MT
22-03-07 UBS Adjusts Afya Price Target to $21 From $27, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+10.26%
- - -7.31%
+38.72%
+63.1%
+66.46%
+52.69%
+91.5%
+70.5%
Average +48.24%
Weighted average by Cap. +21.83%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
55.02BRL
Average target price
88.98BRL
Spread / Average Target
+61.72%
High Price Target
100.86BRL
Spread / Highest target
+83.32%
Low Price Target
76.39BRL
Spread / Lowest Target
+38.84%

Analyst Consensus Detail

Analyst consensus - Afya Limited

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Afya Limited
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Afya Limited